Nightingale Health secured funding of EUR 8.8 million, Leena Niemistö appointed as member of the Board
Finnish health tech company Nightingale Health Oy (“Nightingale”) has successfully completed a funding round aimed at strengthening the company’s working capital while the company is investigating the possibility of listing its shares on the Nasdaq First North Growth Market. The company’s goal was to secure funding of EUR 6–8 million in total, but thanks to strong interest in the funding round, the total amount increased to EUR 8.8 million.
The funding round attracted investments from a group of leading Finnish private investors, including the Chairman of the Board of Nightingale Timo Soininen, Markku Kaloniemi, Mikko Kodisoja, the Langenskiöld family investment firm, and Leena Niemistö.
“The strengthening of our working capital succeeded beyond our goals – we are now in a good position to continue with our plan,” says Teemu Suna, CEO of Nightingale.
Leena Niemistö to the Board of Nightingale
The Board of Directors of Nightingale has appointed Leena Niemistö (b. 1963) as a member of the Board in an Extraordinary General Meeting held on January 7, 2021. Niemistö brings strong experience in driving the growth of both listed and unlisted companies to the Board of Nightingale.
Niemistö is one of the most prominent and influential female decision makers in Finnish business life, an awarded board professional and experienced startup investor. She holds key board positions at numerous companies and organizations, including Nextim Oyj, Pihlajalinna Oyj, Raisio Oyj, Stockmann Oyj, the Finnish National Opera and Ballet, Suomen Messut Osuuskunta and Yliopiston Apteekki. Niemistö is an investor in 35 startups and holds board positions in six of them. In addition to her board position, Niemistö has made an investment in Nightingale.
Niemistö holds a Doctor of Medicine degree. She owned and successfully managed Medical Center Dextra, which she sold to Pihlajalinna in 2012.
“We are extremely pleased to have Leena on the Board of Nightingale. She strengthens our understanding of the health technology business in the Board,” says Timo Soininen, Chairman of the Board of Nightingale.
“Nightingale offers a solution for preventive health on the level of the individual, company and society. I am absolutely thrilled to be part of the revolution of preventive health,” says Leena Niemistö.
For further information:
Teemu Suna
CEO, Nightingale Health Oy
email: teemu.suna@nightingalehealth.com
Timo Soininen
Chairman of the Board, Nightingale Health Oy
email: timo.soininen@nightingalehealth.com
Leena Niemistö
Board member, Nightingale Health Oy
email: leena.niemisto@nightingalehealth.com
Nightingale Health is a health technology company transforming preventive care. We envisage a world that focuses on keeping people healthy rather than just treating illnesses. By combining our pioneering blood-testing technology and the ability to detect future disease risks comprehensively, we are creating a world-leading health data platform that enables better preventative care with better information. The platform helps people make better personal health decisions and connects the health industry to offer their services for individuals’ preventative needs. By empowering the world with better health insights, we accelerate scientific discoveries, industry developments and betters personal health for everyone.
Tags:
